5-HT₃ Receptor ( IC50 = 70.1 nM )

Tropisetron (1 mg/kg i.p.) dramatically improves the impaired inhibitory processing of the P20-N40 auditory evoked potential in DBA/2 mice.[5]

---

Tropisetron is a potent and selective serotonin 3 (5-hydroxytryptamine3; 5-HT3) receptor antagonist with antiemetic properties, probably mediated via antagonism of receptors both at peripheral sites and in the central nervous system. When compared with antiemetic regimens containing high-dose metoclopramide in a small number of studies, tropisetron was generally as effective at preventing acute and delayed vomiting induced by high-dose cisplatin (> or = 50 mg/m2). In these studies tropisetron completely prevented vomiting occurring in the first 24 hours after chemotherapy in 35 to 76% of patients. Tropisetron was superior to alizapride in preventing emesis induced by high-dose alkylating agents. The effectiveness of tropisetron in patients who had previously had partial control of emesis was improved by the addition of dexamethasone. Tropisetron appears to be well tolerated with the most frequently reported adverse effect being headache. Extrapyramidal effects, which can occur in 5 to 10% of patients receiving high-dose metoclopramide and which may limit its use, have been reported in only isolated cases with tropisetron. Thus, tropisetron is an effective, apparently well tolerated agent which can be administered once daily for the prevention of chemotherapy-induced nausea and vomiting. However, further clinical experience is needed to clarify the optimum role of tropisetron as an antiemetic agent, particularly with regard to other drugs in its class. Nonetheless, preliminary results indicate that tropisetron will be a useful alternative for use in controlling emesis induced by cytotoxic therapy. [2]

---

Administration of tropisetron (1 mg/kg i.p.) significantly improved the deficient inhibitory processing of the P20-N40 auditory evoked potential in DBA/2 mice. Coadministration of methyllycaconitine (MLA; 3 mg/kg i.p.), a partially selective antagonist at alpha 7 nicotinic receptors, significantly blocked the normalizing effect of tropisetron. Furthermore, MLA alone did not alter the deficient inhibitory processing of the P20-N40 auditory evoked potential in DBA/2 mice. Conclusions: The data suggest that tropisetron improves the deficient inhibitory processing of the P20-N40 auditory evoked potential in DBA/2 mice by effects on alpha 7 and perhaps alpha 4 beta 2 nicotinic receptors. Tropisetron may be useful for the treatment of deficient inhibitory processing in schizophrenia [5].

The 5-HT3 receptor antagonist tropisetron (ICS 205-930) was found to be a potent and selective partial agonist at alpha7 nicotinic receptors. Two other 5-HT3 receptor antagonists, ondansetron and LY-278,584, were found to lack high affinity at the alpha7 nicotinic receptor. Quinuclidine analogues (1 and 2) of tropisetron were also found to be potent and selective partial agonists at alpha7 nicotinic receptors. [1]

---

Tropisetron, an antagonist of serotonin type 3 receptor, has been investigated in chronic inflammatory joint process. Since T cells play a key role in the onset of several inflammatory diseases, we have evaluated the immunosuppressive activity of tropisetron in human T cells, discovering that this compound is a potent inhibitor of early and late events in TCR-mediated T cell activation. Moreover, we found that tropisetron specifically inhibited both IL-2 gene transcription and IL-2 synthesis in stimulated T cells. To further characterize the inhibitory mechanisms of tropisetron at the transcriptional level, we examined the DNA binding and transcriptional activities of NF-(kappa)B, NFAT and AP-1 transcription factors in Jurkat T cells. We found that tropisetron inhibited both the binding to DNA and the transcriptional activity of NFAT and AP-1. We also observed that tropisetron is a potent inhibitor of PMA plus ionomycin-induced NF-(kappa)B activation but in contrast TNF(alpha)-mediated NF-(kappa)B activation was not affected by this antagonist. Finally, overexpression of a constitutively active form of calcineurin indicated that this phosphatase may represent one of the main targets for the inhibitory activity of tropisetron. These findings provide new mechanistic insights into the anti-inflammatory activities of tropisetron, which are probably independent of serotonin receptor signalling and highlight their potential to design novel therapeutic strategies to manage inflammatory diseases [3].

Cell survival was increased to an average of 105% in retinal ganglion cells (RGCs) pretreated with 100 nM tropisetron before glutamate, in comparison to controls. Tropisetron is thought to be an efficient neuroprotective agent against glutamate-induced excitotoxicity, as it is mediated by α7 nAChR activation, according to inhibition studies conducted with the alpha7 nAChR antagonist MLA (10 nM2). p38 MAPK levels linked to excitotoxicity were dramatically reduced by tropisetron from an average of 15 ng/ml to 6 ng/ml, while pAkt levels were not affected in any appreciable way. Tropisetron over-expresses the CB(1) receptors at both transcriptional and protein levels, inhibits the phosphatase activity of calcineurin significantly (but not granisetron), and lowers the amount of cAMP in cerebellar granule neurons

The ratio of the amplitudes of response to the second (test) stimulus and the first (conditioning) stimulus provides a measure of sensory inhibition; the ratio of the test to the conditioning amplitude (TC ratio) is 0.5 or less for most rodent strains and normal humans (Stevens et al. 1996). Four records were obtained before any drug injection to establish baseline sensory processing performance. Each mouse was drug naive at the time of experimentation. To determine the optimal agonist dose of tropisetron, we examined several doses in a preliminary experiment (0.3, 1, and 3 mg/kg). The 1- and 3-mg/kg doses improved the inhibition of P20–N40 responses in DBA/2 mice. Therefore, the lowest effective dose (1 mg/kg) was selected for further study in comparison with saline vehicle in groups of eight mice. In a subsequent group of studies, the antagonist MLA was administered peripherally (3 mg/kg in saline i.p.), a dose that results in brain levels adequate to antagonize α7 nicotinic receptors (Turek et al. 1995). Recordings were obtained at 5-min intervals for 20 min before and 60 min after injection of each substance. [5]

---

1 mg/kg i.p.

Mice

Absorption, Distribution and Excretion
The absorption of tropisetron from the gastrointestinal tract is rapid (mean half-life of about 20 minutes) and nearly complete (more than 95%). Due to first-pass metabolism in the liver, the absolute bioavailability of a 5 mg oral dose is 60%. The peak plasma concentration is attained within three hours.
About 8% of tropisetron is excreted in the urine as unchanged drug, 70% as metabolites; 15% is excreted in the feces.
400-600 L.
1800 ml/min.

---

Metabolism / Metabolites
The metabolism of tropisetron occurs by hydroxylation at the 5, 6 or 7 positions of its indole ring, followed by a conjugation reaction to the glucuronide or sulphate with excretion in the urine or bile (urine to faeces ratio 5:1). The metabolites have a greatly reduced potency for the 5-HT3 receptor and do not contribute to the pharmacological action of the drug.
Tropisetron has known human metabolites that include 8-Azabicyclo[3.2.1]octan-3-yl 1H-indole-3-carboxylate, (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 5-hydroxy-1H-indole-3-carboxylate, and (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 6-hydroxy-1H-indole-3-carboxylate.

---

Biological Half-Life
5.7 h.

Protein Binding
71% bound to plasma protein in a non-specific manner.

---

rat LD50 oral 265 mg/kg Gekkan Yakuji. Pharmaceuticals Monthly., 40(2445), 1998
rat LD50 intravenous 31400 ug/kg Gekkan Yakuji. Pharmaceuticals Monthly., 40(2445), 1998
mouse LD50 oral 487 mg/kg Gekkan Yakuji. Pharmaceuticals Monthly., 40(2445), 1998
mouse LD50 intravenous 37900 ug/kg Gekkan Yakuji. Pharmaceuticals Monthly., 40(2445), 1998

[1]. Bioorg Med Chem Lett. 2001 Feb 12;11(3):319-21.

[2]. Drugs. 1993 Nov;46(5):925-43.

[3]. Biochem Pharmacol. 2005 Aug 1;70(3):369-80.

[4]. Neuropharmacology. 2013 Oct:73:111-21.

[5]. Psychopharmacology (Berl). 2005 Nov;183(1):13-9.

Tropisetron is an indolyl carboxylate ester obtained by formal condensation of the carboxy group of indole-3-carboxylic acid with the hydroxy group of tropine. It has a role as a serotonergic antagonist, an antiemetic, a nicotinic acetylcholine receptor agonist, a trypanocidal drug, an immunomodulator, a neuroprotective agent, an apoptosis inhibitor and an anti-inflammatory agent. It is an indolyl carboxylate ester, an azabicycloalkane and a tertiary amino compound. It is functionally related to an indole-3-carboxylic acid and a tropine. It is a conjugate base of a tropisetron(1+).
Tropisetron is an indole derivative with antiemetic activity. As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. Tropisetron appears to be well tolerated with the most frequently reported adverse effect being headache. Extrapyramidal side effects are rare upon using tropisetron.
Tropisetron is an indole derivative with antiemetic activity. As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy-and radiotherapy-induced nausea and vomiting. (NCI04)
An indole derivative and 5-HT3 RECEPTOR antagonist that is used for the prevention of nausea and vomiting.

---

Drug Indication
For the prevention of nausea and vomiting induced by cytotoxic therapy and postoperative.

---

Mechanism of Action
Tropisetron competitively binds to and blocks the action of serotonin at 5HT3 receptors peripherally on vagus nerve terminals located in the gastrointestinal (GI) tract as well as centrally in the chemoreceptor trigger zone (CTZ) of the area postrema of the central nervous system (CNS). This results in the suppression of chemotherapy- and radiotherapy-induced nausea and vomiting.

---

In conclusion, the present study suggests that tropisetron improves the deficient inhibitory processing of the P20–N40 auditory evoked potential in DBA/2 mice through α7, and perhaps α4β2, nicotinic receptors. Tropisetron (Koike et al. 2005) thus joins clozapine as a medication that increases the inhibitory processing of auditory evoked responses in humans (Nagamoto et al. 1996, 1999) and animals (Simosky et al. 2003), and the two medications appear to share a common end effect on nicotinic receptors, especially the α7 subtype. If the correlation between failure of sensory inhibition and neurophysiological measures of attentional dysfunction in schizophrenia (Cullum et al. 1993) reflects a common neurobiological mechanism, then 5-HT3 antagonists, such as tropisetron and ondansetron, may offer a treatment option for attentional problems, and perhaps cognitive difficulties, often experienced by schizophrenia patients.[5]

C17H21CLN2O2

320.81

320.129

C, 64.57; H, 6.92; Cl, 10.59; N, 8.37; O, 9.56

105826-92-4

Tropisetron; 89565-68-4

656665

White to off-white solid powder

448.5ºC at 760 mmHg

283-285ºC

225ºC

3.09E-08mmHg at 25°C

2.83

1

3

3

21

400

2

Cl[H].O(C(C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12)=O)C1([H])C([H])([H])[C@]2([H])C([H])([H])C([H])([H])[C@]([H])(C1([H])[H])N2C([H])([H])[H]

XIEGSJAEZIGKSA-KOQCZNHOSA-N

InChI=1S/C17H20N2O2.ClH/c1-19-11-6-7-12(19)9-13(8-11)21-17(20)15-10-18-16-5-3-2-4-14(15)16;/h2-5,10-13,18H,6-9H2,1H3;1H/t11-,12+,13?;

[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate;hydrochloride

ICS-205-930; Tropisetron; ICS-205930; 105826-92-4; Tropisetron hydrochloride; TROPISETRON HCl; Tropisetron monohydrochloride; Tropisetron (Hydrochloride); (1R,3r,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 1H-indole-3-carboxylate hydrochloride; SDZ-ICS-930; [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate;hydrochloride; ICS 205930; ICS205930; ICS 205-930; Tropisetron HCl; Brand name: Navoban

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: Please store this product in a sealed and protected environment, avoid exposure to moisture.

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Solubility in Formulation 1: 120 mg/mL (374.05 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.

---

 (Please use freshly prepared in vivo formulations for optimal results.)